Skip to main
ORGO

Organogenesis Holdings (ORGO) Stock Forecast & Price Target

Organogenesis Holdings (ORGO) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Organogenesis Holdings is a solid investment opportunity due to its diverse portfolio in the regenerative medicine market. While challenges in the Advanced Wound Care market may affect the stock in the short term, ORGO's strong cash balance and potential for growth make it a reliable long-term investment. Additionally, the company's focus on minimal market disruption and strong product portfolio bode well for its success in the growing market, as shown by the positive results of studies on its products.

Bears say

Organogenesis Holdings is a regenerative medicine company with a negative outlook based on several factors. First, their projected FY26 guidance of $350M-$420M represents a significant decline of 38%-25% year over year, with a targeted 50% decline in 1Q26. Secondly, Organogenesis faces competition from other companies in the regenerative medicine market and may struggle to gain market share. Finally, potential issues with Medicare pricing and lower-than-expected uptake of new products may also pose a risk to the company's growth and success.

Organogenesis Holdings (ORGO) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Organogenesis Holdings (ORGO) Forecast

Analysts have given Organogenesis Holdings (ORGO) a Buy based on their latest research and market trends.

According to 2 analysts, Organogenesis Holdings (ORGO) has a Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Organogenesis Holdings (ORGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.